Copyright © 2024 Cirsium Biosciences. All Rights Reserved.
Menu
By using plants as production base unit, our platform uses a linear scale out production model.
This enables swift and reproducible scaling, without the need for significant process development, unlike traditional AAV production.
Our platform significantly expedites process development through the synergy of modular plant production technology, plant reproducibility, and immediate production capacity access, eliminating high-purity plasmid delays.
Our process achieves up to 70% reduction in manufacturing lead times for vital gene therapies, offering patients expedited access and life-saving opportunities.
Utilizing a non-GMP upstream controlled environment agriculture (CEA) space, our platform produces up to 1e15vg/kg of recombinant AAV vector.
This brings significant cost reductions when compared to traditional cGMP facilities.
Our platform simplifies the supply chain and reduces batch failures using a human pathogen resistant platform.
Copyright © 2024 Cirsium Biosciences. All Rights Reserved.